Suppr超能文献

HIV-1 整合酶在整合酶抑制剂首次获得批准前 20 年的分子进化。

Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.

机构信息

HIV and other Retroviruses, Robert Koch Institute, Berlin, Germany.

Department of Mathematics and Computer Science, Freie Universität Berlin, Berlin, Germany.

出版信息

Virol J. 2017 Nov 14;14(1):223. doi: 10.1186/s12985-017-0887-1.

Abstract

BACKGROUND

Detailed knowledge of the evolutionary potential of polymorphic sites in a viral protein is important for understanding the development of drug resistance in the presence of an inhibitor. We therefore set out to analyse the molecular evolution of the HIV-1 subtype B integrase at the inter-patient level in Germany during a 20-year period prior to the first introduction of integrase strand inhibitors (INSTIs).

METHODS

We determined 337 HIV-1 integrase subtype B sequences (amino acids 1-278) from stored plasma samples of antiretroviral treatment-naïve individuals newly diagnosed with HIV-1 between 1986 and 2006. Shannon entropy was calculated to determine the variability at each amino acid position. Time trends in the frequency of amino acid variants were identified by linear regression. Direct coupling analysis was applied to detect covarying sites.

RESULTS

Twenty-two time trends in the frequency of amino acid variants demonstrated either single amino acid exchanges or variation in the degree of polymorphy. Covariation was observed for 17 amino acid variants with a temporal trend. Some minor INSTI resistance mutations (T124A, V151I, K156 N, T206S, S230 N) and some INSTI-selected mutations (M50I, L101I, T122I, T124 N, T125A, M154I, G193E, V201I) were identified at overall frequencies >5%. Among these, the frequencies of L101I, T122I, and V201I increased over time, whereas the frequency of M154I decreased. Moreover, L101I, T122I, T124A, T125A, M154I, and V201I covaried with non-resistance-associated variants.

CONCLUSIONS

Time-trending, covarying polymorphisms indicate that long-term evolutionary changes of the HIV-1 integrase involve defined clusters of possibly structurally or functionally associated sites independent of selective pressure through INSTIs at the inter-patient level. Linkage between polymorphic resistance- and non-resistance-associated sites can impact the selection of INSTI resistance mutations in complex ways. Identification of these sites can help in improving genotypic resistance assays, resistance prediction algorithms, and the development of new integrase inhibitors.

摘要

背景

详细了解病毒蛋白中多态性位点的进化潜力对于理解在抑制剂存在下药物耐药性的发展非常重要。因此,我们着手分析在整合酶链转移抑制剂(INSTIs)首次引入之前的 20 年中,德国患者间 HIV-1 亚型 B 整合酶的分子进化。

方法

我们从 1986 年至 2006 年间新诊断为 HIV-1 的接受抗逆转录病毒治疗的个体的储存血浆样本中确定了 337 个 HIV-1 整合酶亚型 B 序列(氨基酸 1-278)。计算香农熵以确定每个氨基酸位置的变异性。通过线性回归确定氨基酸变异频率的时间趋势。应用直接耦联分析来检测共变位点。

结果

22 个氨基酸变异频率的时间趋势表明,存在单个氨基酸交换或多态性程度的变化。与时间趋势相关的共变观察到 17 个氨基酸变体。一些较小的 INSTI 耐药突变(T124A、V151I、K156N、T206S、S230N)和一些 INSTI 选择的突变(M50I、L101I、T122I、T124N、T125A、M154I、G193E、V201I)的总体频率>5%。其中,L101I、T122I 和 V201I 的频率随时间增加,而 M154I 的频率降低。此外,L101I、T122I、T124A、T125A、M154I 和 V201I 与非耐药相关变体共变。

结论

时间趋势、共变多态性表明,HIV-1 整合酶的长期进化变化涉及到与结构或功能相关的特定簇,而不受患者间水平通过 INSTIs 的选择压力的影响。多态性耐药和非耐药相关位点之间的联系可能以复杂的方式影响 INSTI 耐药突变的选择。鉴定这些位点有助于改进基因型耐药性检测、耐药性预测算法和新型整合酶抑制剂的开发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc2f/5686839/8b4fb4f58c77/12985_2017_887_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验